Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752332 · ClinicalTrials.gov registry record · Phase 3
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT04752332 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 111 participants.
The verdict
NCT04752332, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.
Interventions
- DRUG Placebo
- DRUG Abemaciclib
- DRUG Standard Adjuvant ET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752332
The ClinicalTrials.gov registry entry for NCT04752332 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04752332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04752332 about?
NCT04752332 is a clinical study titled "A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer". The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participat...
What is the current status of trial NCT04752332?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2021-05-10. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT04752332?
The interventions under investigation include: Placebo (DRUG), Abemaciclib (DRUG), Standard Adjuvant ET (DRUG).
Who is sponsoring clinical trial NCT04752332?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.